India's vast population will have access from today to the Australian developed 
anti-COVID nasal spray Viraleze™ following its registration in the country.

The announcement came as the world's second most populous country battles a 
devastating second wave of COVID-19 infections, with over 29 million cases and 
363,000 deaths. Yesterday, India set a new global record for deaths after 6,148 
people died in the previous 24 hours.

Developed by biopharmaceutical company Starpharma, Viraleze™ has shown to 
inactivate a broad-spectrum of respiratory viruses, including more than 99.9% 
of coronavirus SARS-CoV-2 (the virus that causes COVID-19). The product can be 
applied before or after exposure and can be used in high-risk or crowded 
environments up to four times a day. 

Importantly for a largely rural population like India's, the spray can be 
stored at room temperature and does not require cold storage or specialised 
transportation.

Indian consumers can purchase the spray from www.viraleze.co and Starpharma's 
discussions with commercial partners in India for distribution into both the 
private (consumer) and Government markets are well advanced.

"India continues to record hundreds of thousands of COVID-19 cases every day. 
Starpharma has worked extremely hard to achieve expedited registration of 
Viraleze™ given the significant need," said Starpharma's CEO, Dr Jackie 
Fairley.  

"The active in Viraleze™, astodrimer sodium, has been shown to be highly active 
against multiple strains and variants of SARS-CoV-2, including the problematic 
Alpha variant( https://starpharma.com/news/589 ), which is the second most 
common variant in India and has been responsible for COVID-19 cases in about 
135 countries."

Viraleze™ first launched in the UK at LloydsPharmacy in March and was the 
biggest selling product ever at LloydsPharmacy.com. It launched in Europe in 
May. 

Starpharma has received interest from more than 30 countries since launching 
its webstore, including from Japan where the Olympics soon begin, and has been 
in the grip of a fourth wave of COVID-19 infections.

Viraleze™ has also been ordered by several international sporting teams, 
including Olympic teams. Starpharma has signed a partnership agreement for 
Viraleze™ with the Harlequins rugby union team in the UK which are using the 
product as part of its COVID-19 prevention protocols.  

Viraleze™ complements other COVID-19 prevention strategies, including vaccines. 
It has special relevance in areas of high population density, and where social 
distancing is not possible and in high-risk environments such as travel, hotel 
quarantine, and sporting events. 

SOURCE  Starpharma

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=393614

   Caption: Starpharma